Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form

Objectives: Ertugliflozin is a selective sodium-glucose cotransporter 2 inhibitor approved for the treatment of type 2 diabetes in adults. In its natural form, ertugliflozin exists as an amorphous solid with physicochemical properties that prevent commercial manufacture. The commercial product was d...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahasrabudhe, Vaishali, Matschke, Kyle, Shi, Haihong, Hickman, Anne, Kong, Angela, Rodríguez Spong, Barbara, Nickerson, Beverly, Arora, Kapildev K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238437/
https://www.ncbi.nlm.nih.gov/pubmed/35575420
http://dx.doi.org/10.5414/CP204212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238437/
https://www.ncbi.nlm.nih.gov/pubmed/35575420
http://dx.doi.org/10.5414/CP204212

Ejemplares similares